Advaxis, Inc a clinical stage biotechnology company developing cancer immunotherapies, will unveil its new state-of-the-art manufacturing facility in Princeton, N.J., with remarks from Governor Chris Christie, BioNJ President and CEO Debbie Hart and Advaxis CEO Daniel O’Connor.
The facility enables Advaxis to manufacture clinical-grade immuno-oncology product candidates for hundreds of patients enrolled in several trials for multiple cancer types, as well as the capability to manufacture commercial-grade products in the future, including personalized cancer treatments that are being developed as part of its MINE™ (My Immunotherapy Neo-Epitopes) program.
WHERE: Advaxis, Inc.
305 College Road
East Princeton, NJ 08540
WHEN: Friday, September 9, 2016 – 11 a.m. EDT
Developing immunotherapies that capitalize on the body’s ability to recognize and attack bacterial infections, using the core Lm Technology™ is Advaxis’ number one priority in helping patients. This facility allows Advaxis to manufacture these immunotherapies efficiently and cost-effectively in-house, while nearly doubling the company’s corporate footprint to 48,511 sq. ft. As an epicenter of innovation, the team is proud to continue growing our New Jersey headquarters.
WHO: Advaxis welcomes New Jersey Gov. Christopher J. Christie and other distinguished guests to attend the unveiling, as they celebrate this important corporate milestone.
About Advaxis, Inc.
Located in Princeton, N.J., Advaxis, Inc. is a clinical-stage biotechnology company developing multiple cancer immunotherapies based on its proprietary Lm Technology™. The Lm Technology, using bioengineered live attenuated Listeria monocytogenes (Lm) bacteria, is the only known cancer immunotherapy agent shown in preclinical studies to both generate cancer fighting T cells directed against cancer antigens and neutralize Tregs and myeloid-derived suppressor cells (MDSCs) that protect the tumor microenvironment from immunologic attack and contribute to tumor growth. Advaxis’ lead Lm Technology immunotherapy, AXAL, targets human papillomavirus (HPV)-associated cancers and is in clinical trials for three potential indications: Phase 3 in invasive cervical cancer, Phase 2 in head and neck cancer, and Phase 2 in anal cancer. The FDA has granted AXAL orphan drug designation for each of these three clinical settings, as well as Fast Track designation for adjuvant therapy for HRLACC patients and a Special Protocol Assessment for the Phase 3 AIM2CERV trial in HRLACC patients. AXAL has also been classified as an advanced therapy medicinal product for the treatment of cervical cancer by the European Medicines Agency’s Committee for Advanced Therapies. Advaxis has two additional immunotherapy products: ADXS-PSA in prostate cancer and ADXS-HER2 in HER2 expressing solid tumors, in human clinical development. In addition, Advaxis and Amgen are developing ADXS-NEO, a preclinical investigational cancer immunotherapy treatment designed to activate a patient’s immune system to respond against the unique mutations, or neoepitopes, contained in and identified from each individual patient’s tumor, with plans to enter the clinic in 2017.
For additional information on Advaxis,
visit www.advaxis.com
Contact:
JPA Health Communications
David Connolly
dconnolly@jpa.com
617-543-3915
